IP Library Granted Patent US 10,695,403
Granted Patent B2
US 10,695,403 · App. 15/739,238 · Granted Jun 30, 2020

Use of FGF19 to increase muscle fiber size

Inventors: Emmanuelle Fouilloux-Meugnier (Oullins, FR); Hubert Vidal (Saint Genis Laval, FR); Jérome Ruzzin (Morvik, NO)
Assignees: Universite Claude Bernard Lyon; Institut National de la Recherche Agronomique (INRA); Institut National de la Santè et de la Recherche Médicale (INSERM); Bergen Teknologioverforing AS
A61K38/1825A61K45/06A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,695,403
App. No.
15/739,238
Granted
Jun 30, 2020
Kind
B2
Abstract

The present invention relates to an FGF19 polypeptide for use in increasing muscle fiber size in the treatment of muscle atrophy in a mammal.

Claims (13)

1. A method for increasing the muscle fiber size in a mammal wherein the mammal has muscle atrophy, said method comprising administering an effective amount of a fibroblast growth factor 19 (FGF19) polypeptide to the mammal.

2. The method according to claim 1 , wherein the mammal is a human.

3. The method according to claim 1 , wherein an increase in muscle mass in the mammal is observed.

4. The method according to claim 1 , wherein the mammal is not a human.

5. The method according to claim 1 , wherein muscle strength is increased in the mammal.

6. The method according to claim 1 , wherein the FGF19 polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.

7. The method according to claim 1 , wherein the muscle atrophy is caused by cachexia.

8. The method according to claim 1 , wherein the muscle atrophy is caused by sarcopenia.

9. The method according to claim 1 , wherein the muscle atrophy is caused by prolonged immobilization.

10. The method according to claim 1 , wherein the muscle atrophy is caused by obesity.

11. The method according to claim 1 , wherein the mammal is a bovine.

12. A method for increasing the muscle fiber size in a mammal wherein the mammal has muscle atrophy, said method comprising administering an effective amount of a pharmaceutical composition comprising and FGF19 polypeptide and a pharmaceutically-acceptable vehicle to the mammal.

13. The method according to claim 12 , wherein the pharmaceutical composition further comprises a drug for treating cachexia, a performance-enhancing drug, a nutritional supplement, a solution of amino acids, or protein hydrolysates.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 052469 FRAME 0167. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Apr 28, 2020
From: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
To: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
Reel/Frame 052510/0160 →
CHANGE OF NAME Recorded Apr 22, 2020
From: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
To: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE)
Reel/Frame 052469/0167 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: FOUILLOUX-MEUGNIER, EMMANUELLE; VIDAL, HUBERT; RUZZIN, JEROME
To: UNIVERSITE CLAUDE BERNARD LYON; INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); BERGEN TEKNOLOGIOVERFORING AS
Reel/Frame 049059/0887 →